Scinopharm Taiwan, Ltd. · TWSE:1789
Scinopharm Taiwan — Investor Presentation (March 2012)
27 slides from Scinopharm Taiwan's investor presentation, Mar 14, 2012
Slide 1: ScinoPharm Management Presentation
ScinoPharm Management Presentation TWSE 1789 March 14-15, 2012
Slide 2: Disclaimer
Confidential Disclaimer This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”). Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information cont
Slide 3: Table of Content
Confidential Table of Content Overview of ScinoPharm Financial & Operation Results India – Passage to US/EU Business Outlook Q&A 3
Slide 4: Overview of ScinoPharm
Overview of ScinoPharm 4
Slide 5: Company Overview
Confidential Company Overview Maintain dominant position in Specialty API for generic market Developed more than 50 generic APIs with 16 launched, provided to around 300 customers Filed 41 DMF in US FDA (587 DMF worldwide), kept leading position in oncology injectable APIs with 19 US DMF, far exceed
Slide 6: Company Overview – cont’d
Confidential Company Overview – cont’d Heavy emphasis on R&D, with 88 patents granted worldwide to 18 inventions Established a strong presence in US/EU generic market, part of which was channeled through Indian generic companies, began to develop Japanese and Chinese markets Expanding both Taiwan an
Slide 7: World Class Facilities
Confidential World Class Facilities Taiwan China 6.6 hectares of land, 330K sqft facilities With nearly 250M3 reactor volume with >200M3 reactor volume after 2 large product lines expansion The first phase completed by the end of 2011. The second phase completed by the Six of our production lines ar
Slide 8: ScinoPharm – Top Ranking in Oncology DMF among API companies
Confidential ScinoPharm – Top Ranking in Oncology DMF among API companies 8
Slide 9: Top Generic APIs Account for 66% of 2011 sales
Confidential Top 5 Generic APIs Account for 66% of 2011 sales 2011 # of US DMF/EDMF & API Indications projected other Filings MKT Share* Docetaxel 38% Anti-Cancer 53 Anhydrous (WW) 44% Irinotecan HCI Anti-Cancer 47 (WW) 49% Galantamine HBr Alzheimer’s disease 36 (WW) 21% Paclitaxel Anti-Cancer 47 (W
Slide 10: Financial & Operation Results
Financial & Operation Results 10
Slide 11: P&L – 4Q 2011
Confidential P&L – 4Q 2011 4Q,’11 3Q,’11 4Q,’10 NT$MM, except EPS QoQ YoY (unaudited) (reviewed) (audited) Net Sales 1,127 1,062 1,115 6% 1% Gross Profit 559 483 508 16% 10% Gross margin 50% 46% 46% SG&A (207) (186) (198) 11% 5% Operating Income 352 297 311 19% 13% Operating Margin 31% 28% 28% Other
Slide 12: P&L - FY2011
Confidential P&L - FY2011 FY 2011 FY 2010 NT$MM, except EPS YoY (unaudited) (audited) Net Sales 3,948 3,887 2% Gross Profit 1,885 1,940 -3% Gross margin 48% 50% SG&A (742) (744) -0% Operating Income 1,144 1,196 -4% Operating margin 29% 31% Other Rev.(Exp.) (20) (11) 81% Net Income before Tax 1,124 1
Slide 13: Balance Sheet
Confidential Balance Sheet NT$MM 2011/12/31 2010/12/31 (unaudited) (audited) Cash and Cash Equivalents 3,080 33% 1,741 24% Accounts Receivable 844 9% 731 10% Inventories 1,450 15% 1,244 17% Long-Term Investments 1,133 12% 671 9% Fixed Assets 2,592 28% 2,592 36% Total Assets 9,415 100% 7,287 100% Cur
Slide 14: Cash Flows
Confidential Cash Flows FY 2011 FY 2010 NT$MM (unaudited) (audited) Cash and cash equivalents at 1,742 489 beginning of year Cash flows from operating activities 1,269 1,556 CAPEX (344) (172) Long-Term Investment (450) (370) Issuance of common stock 957 1,173 Repayment of Long-Term Loans - (937) Oth
Slide 15: Sales by Business
Confidential Sales by Business 2010 2011 CMO CMO 2.5% 13.4% CRO CRO 6.6% 2.4% Generic Generic 90.9% 84.2% 15
Slide 16: Sales by Indications
Confidential Sales by Indications 2010 2011 Others Others 29.6% 37.8% 學名藥 90.91% 16
Slide 17: Sales by Region
Confidential Sales by Region 2010 2011 ROW ROW AU & NZ 1% AU & NZ 0% 6% 6% US & CAN US & CAN 33% 38% EU EU 32% 30% Asia Asia 28% 26% Out of the 26% Asia sales in 2011, India was 17%, rest of Asia was 9% 17
Slide 18: India – A Passage to US/EU markets
India – A Passage to US/EU markets 18
Slide 19: India – A Passage to US/EU markets
India – A Passage to US/EU markets More and more US/EU pharma outsourced formulations to India because of India’s mature pharma industry, low-cost production, comparable quality, and language skill 175 Indian pharma companies have been qualified for US FDA standards. Indian ownership of approved US
Slide 20: Top 10 Indian Pharma Companies
Top 10 Indian Pharma Companies Ran Revenue 2010 Pharma Co. k (USD $MM) 1 Cipla 1,348.5 8 out of the top 10 2 Ranbaxy 1,327.6 are ScinoPharm’s 3 Dr. Reddy’s Lab 1,178.0 customers 4 Lupin Ltd 929.8 5 Aurobindo 865.2 6 Dabur 700.3 7 Sun Pharmac 674.0 8 Cadila 629.5 9 Jubilant 561.0 10 Piramal 480.3 20
Slide 21: ScinoPharm - Broad Customer Base in India
ScinoPharm - Broad Customer Base in India Customers 2006 2007 2008 2009 2010 2011 2012 (est.) # of New additions 13 3 8 5 8 2 3 # of accumulated customers 13 16 24 29 37 39 42 21
Slide 22: ScinoPharm Successfully Penetrated US/EU Markets Through India
ScinoPharm Successfully Penetrated US/EU Markets Through India ScinoPharm’s Business via India (2006 - 2012) 22
Slide 23: Business Outlook
Business Outlook 23
Slide 24: 2012 Product Launch Plan
2012 Product Launch Plan Regional WW Sales API Region Indications Brand Marketer Sales Argatroban Antithrombotic, $US $US US GSK Anticoagulant 139MM* 205MM* Galantamine Alzheimer’s $US $US EU Janssen HBr disease 314MM* 527MM* $US $US Modafinil US Antinarcolepsy Cephalon 1,078MM* 1,182MM* Riluzole $U
Slide 25: Entering Chinese Market
Entering Chinese Market API SPT Strategic Alliance China Import API Pharma Formulations SPC Market Strategic Alliance 25
Slide 26: Outlook
Confidential Outlook Sustain Our Current Leadership Position Continue developing small molecule oncological injectable APIs and expand into other areas with high technology barriers including Peptides and Biopharmaceutical Expand Presences in China Expansion of API business to timely capture the Chi
Slide 27: Brand Quality with Asian Advantages
Confidential Brand Quality with Asian Advantages www.scinopharm.com 27
ScinoPharm Taiwan — Investor Presentation (March 2012) on 6ix